Monodehydroascorbate reductase (MDAR; EC 1.6.5.4) is one of the key enzymes in the conversion of oxidized ascorbate (AsA) back to reduced AsA in plants. This study investigated the role of MDAR in the tolerance of Chlamydomonas reinhardtii P.A. Dangeard to photooxidative stress by overexpression and downregulation of the CrMDAR1 gene. For overexpression of CrMDAR1 driven by a HSP70A:RBCS2 fusion promoter, the cells survived under very high-intensity light stress (VHL, 1,800 μmol�m−2�s−1), while the survival of CC-400 and vector only control (vector without insert) cells decreased for 1.5 h under VHL stress. VHL increased lipid peroxidation of CC-400 but did not alter lipid peroxidation in CrMDAR1 overexpression lines. Additionally, overexpression of CrMDAR1 showed an increase in viability, CrMDAR1 transcript abundance, enzyme activity and the AsA: dehydroascorbate (DHA) ratio. Next, MDAR was downregulated to examine the essential role of MDAR under high light condition (HL, 1,400 μmol�m−2�s−1). The CrMDAR1 knockdown amiRNA line exhibited a low MDAR transcript abundance and enzyme activity and the survival decreased under HL conditions. Additionally, HL illumination decreased CrMDAR1 transcript abundance, enzyme activity and AsA:DHA ratio of CrMDAR1-downregulation amiRNA lines. Methyl viologen (an O2�− generator), H2O2 and NaCl treatment could induce an increase in CrMDAR1 transcript level. It represents reactive oxygen species are one of the factor inducing CrMDAR1 gene expression. In conclusion, MDAR plays a role in the tolerance of Chlamydomonas cells to photooxidative stress.

Aims Patients with interstitial cystitis/bladder pain syndrome (IC/BPS) typically experience anxiety mood status, which is closely connected with physical and psychological status and treatment outcome. This study aimed to evaluate the impact of anxiety severity on therapeutic results in IC/BPS patients. Methods We prospectively enrolled IC/BPS patients who had previously undergone any kind of treatment for their disease. The primary endpoint was a change in Beck Anxiety Inventory (BAI) scores at 3 months after treatment. Secondary endpoints included changes in the Global Response Assessment (GRA), O'Leary‐Sant symptom score (OSS), and Numerical Rating Scale (NRS) at 3 months after treatment. Urodynamic studies were also compared with the clinical symptom scores. Results Overall, 85 IC/BPS patients (mean age, 53.1 ± 12.4 years) were included in the study. At 3 months, changes in the GRA were not significantly different among the different anxiety severity groups. At baseline, 55 (64.7%) patients had moderate or severe anxiety. We observed a significant positive correlation between the change in BAI and the change in OSS after treatment and a significantly negative correlation with GRA at 3 months. Moreover, improvements in OSS and NRS were associated with the change in GRA. Changes in IC symptoms, but not physiological outcomes, were associated with improved anxiety status after treatment. In addition, the change in BAI was significantly associated with age, baseline BAI, and changes in OSS and GRA after treatment. Conclusions Baseline anxiety severity does not influence treatment outcomes of IC/BPS. Patients should receive active treatment regardless of their baseline anxiety status.

Introduction: The aim of this study is to evaluate the characteristics of the dosimetry and the skin dose of interstitial brachytherapy by the use of the free-hand implantation technique toward the treatment of early breast cancer. Materials & Methods: Seventeen patients diagnosed with early breast cancer were selected for the study. The implantation of the catheters for postoperative interstitial brachytherapy was performed using the free-hand technique. The total tumor dose to the tumor cavity plus 2 cm margin was 3400 cGy, twice daily for 10 fractions in 5 days. The dosage to the target and the organ at risk (OAR) were recorded for analysis. The skin dose of the patient and the phantom were measured with Gafchromic film (EBT3) and the results were compared with the skin dose calculated by the brachytherapy treatment planning system. Results: The median conformal index is 94% (range 89%-99%), and the median homogeneity index is 71%. The median skin dose measured from the skin of the patients was 20.1% lower than the skin dose calculated from the treatment planning system and consistent with the phantom surface measurement experiment. There were no grade 3 or above acute toxicity recorded. Conclusions: Interstitial brachytherapy by the use of the free-hand implantation technique for early breast cancer is feasible and avoids the need for a second surgical intervention. The calculated skin dose was overestimated by at least 20%. The results of this study may help in building a modification model for the prediction of skin toxicity in any future study. K E Y W O R D S breast cancer, interstitial brachytherapy, accelerated partial breast irradiation 1 | INTRODUCTION In the era of modern medical practice, the key role of cancer therapy is to give a high cancer control probability, while minimizing the side effects on healthy organs. Conventional whole breast irradiation (WBI) has been a standard adjuvant approach for several decades with regard to early breast cancer after breast conserving surgery (BCS). 1-3 Conventional WBI offers high local control, minimal side